Please login to the form below

Not currently logged in
Email:
Password:

HCC

This page shows the latest HCC news and features for those working in and with pharma, biotech and healthcare.

Lilly’s Cyramza narrowly clears FDA adcomm vote for first-line NSCLC

Lilly’s Cyramza narrowly clears FDA adcomm vote for first-line NSCLC

It’s most recent approval was in hepatocellular carcinoma (HCC) that expresses high levels of the biomarker alpha-fetoprotein (AFP). ... Around 40% of patients with advanced HCC tumours express high levels of AFP – these tumours tend to be more

Latest news

  • Exelixis bounces back with new prostate cancer data Exelixis bounces back with new prostate cancer data

    It is also approved for use under the name Cabometyx in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) – net product revenues from the entire franchise are expected to be between ... It is also testing cabozantinib in combination with

  • Roche files Tecentriq/Avastin combo in liver cancer Roche files Tecentriq/Avastin combo in liver cancer

    Roche has filed Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) as a first-line treatment for unresectable hepatocellular carcinoma (HCC) – the most common form of liver cancer. ... Patients received PD-L1 inhibitor Tecentriq plus

  • AZ’s Imfinzi scores orphan drug status in liver cancer AZ’s Imfinzi scores orphan drug status in liver cancer

    Out of that number of new cases, 42, 000 people were diagnosed with HCC in the US last year. ... According to AZ, HIMALAYA is the first trial to test dual immune checkpoint blockade in the first-line advanced HCC setting.

  • Roche’s Tecentriq/Avastin combo improves survival in liver cancer Roche’s Tecentriq/Avastin combo improves survival in liver cancer

    death by 42% compared to Bayer’s Nexavar (sorafenib) when given as a first-line therapy for hepatocellular carcinoma (HCC) patients ineligible for surgery. ... nivolumab), and Roche has a chance of pipping its rivals to the first-line HCC market.

  • BMS scores FDA priority review for Opdivo/Yervoy combo in liver cancer BMS scores FDA priority review for Opdivo/Yervoy combo in liver cancer

    There are limited treatment options for HCC patients, with only a handful of new agents having been approved in recent years in the second-line setting. ... Opdivo is already approved as a monotherapy second-line treatment for HCC, but the combo could

More from news
Approximately 4 fully matching, plus 40 partially matching documents found.

Latest Intelligence

  • Mining for results Mining for results

    The first product to come from Apixio's technology platform is called the HCC Profiler.

  • Pharma Perspectives: The agency selection process (part 2) Pharma Perspectives: The agency selection process (part 2)

    Samuel Hollis is a business unit director at AstraZeneca. In Pharma Perspectives, published in association with the HCC, senior industry and agency figures address key marketing challenges. ... The Health Communications' Council (HCC) is a specialist

  • Pharma Perspectives: The agency selection process (part 1) Pharma Perspectives: The agency selection process (part 1)

    In Pharma Perspectives, published in association with the HCC, senior industry and agency figures address key marketing challenges. ... The Health Communications' Council (HCC) is a specialist division of the European Association of Communications

  • Pharma perspectives: communications creativity (part 2) Pharma perspectives: communications creativity (part 2)

    David Higgins is UK managing director at Sudler &Hennessey Group. He can be contacted via email: David.Higgins@sudler.com  . In the PME/PMLiVE series Pharma Perspectives with the HCC  senior ... If you have a topic you'd like the series to explore

  • Pharma perspectives: communications creativity (part 1) Pharma perspectives: communications creativity (part 1)

    In the PME/PMLiVE series Pharma Perspectives with the HCC senior industry and agency figures give their thoughts on today's key marketing challenges. ... If you have a topic you'd like the series to explore please send it to editor@pmlive.com  . The

More from intelligence
Approximately 2 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Covid-19 redefines rules of customer engagement
Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs...
Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....
The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....

Infographics